title: Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia.
abstract: Methicillin-resistant Staphylococcus aureus (MRSA) is a significant cause of health care-associated infections. Vancomycin remains an acceptable treatment option. There has been a welcome increase in the number of agents available for the treatment of MRSA infection. These drugs have certain differentiating attributes and may offer some advantages over vancomycin, but they also have significant limitations. These agents provide some alternative when no other options are available.
authors.affiliation: Division of Infectious Diseases, Department of Medicine, Soonchunhyang University Hospital, Bucheon, Korea.
authors.forename: Eun Ju
authors.identifier: 0000-0003-2842-7041
authors.initials: EJ
authors.lastname: Choo
authors.affiliation: Division of Infectious Diseases, Department of Medicine, San Francisco General Hospital, University of California, San Francisco, San Francisco, CA, USA. Henry.Chambers@ucsf.edu.
authors.forename: Henry F
authors.identifier: 0000-0001-5317-4491
authors.initials: HF
authors.lastname: Chambers
keywords: Methicillin-resistant Staphylcoccus aureus; Treatment; Vancomycin